【摘要】 目的探讨沙利度胺联合VAD方案与单用VAD方案治疗初治多发性骨髓瘤(MM)的临床效果及安全性。方法35例初治MM病人在采用VAD方案治疗的基础上,将沙利度胺从小剂量(100mg/d)开始口服,在能耐受的情况下逐渐增加剂量,一般不超过300mg/d。30例MM病人采用VAD方案治疗。结果沙利度胺联合VAD方案组的有效率优于单用VAD方案组(uc=3.19,P<0.05),沙利度胺联合VAD方案组的不良反应有神经毒性、嗜睡、便秘、脱发及感染。结论沙利度胺联合VAD方案治疗初治性MM疗效显著优于VAD方案,缓解率高,是治疗初治性MM效果较好而又安全的方案,应优先考虑使用。更多还原

【Abstract】 Objective To compare the efficacy and safety of Thalidomide-combined-with-VAD(combotherapy) chemotherapy and VAD-alone chemotherapy(VAD alone) for multiple myeloma(MM).MethodsThirty-five cases newly diagnosed MM were enrolled for combotherapy.Thirty patients treated with VAD alone served as controls.ResultsThe response rate in the combotherapy was higher than that in the VAD alone(uc=3.19,P<0.05).The main side reactions in the combotherapy were neurotoxicity,fatigue,lethargy,constipation,alopecie and infection.ConclusionThe combotherapy is an effective and safe re-gimen for newly diagnosed MM and appears significantly superior to VAD alone.更多还原